Variant position: 254 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 860 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human ATCRPDEFQCSDGNCIHGSR QCDREYDCKDMSDEVGCVNVT
Mouse ATCRPDEFQCADGSCIHGSR QCDREHDCKDMSDELGCVNVT
Rat TTCRPDEFQCADGSCIHGSR QCDREHDCKDMSDELGCINVT
Bovine ATCRPDEFQCSDGTCIHGSR QCDREPDCKDLSDELGCVNVT
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
22 – 860 Low-density lipoprotein receptor
22 – 788 Extracellular
234 – 272 LDL-receptor class A 6
272 – 272 N-linked (GlcNAc...) asparagine
243 – 261
105 – 272 Missing. In isoform 3.
273 – 273 V -> L. In isoform 3.
254 – 258
Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.
Bertolini S.; Cantafora A.; Averna M.; Cortese C.; Motti C.; Martini S.; Pes G.; Postiglione A.; Stefanutti C.; Blotta I.; Pisciotta L.; Rolleri M.; Langheim S.; Ghisellini M.; Rabbone I.; Calandra S.;
Arterioscler. Thromb. Vasc. Biol. 20:E41-E52(2000)
Cited for: VARIANTS FHCL1 PHE-134; TRP-134; TYR-222; PRO-254; ARG-276; ARG-318; THR-370; GLY-415 AND TYR-579;
The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M.; Rabes J.-P.; Jambart S.; Halaby G.; Gannage-Yared M.-H.; Sarkis A.; Beaino G.; Varret M.; Salem N.; Corbani S.; Aydenian H.; Junien C.; Munnich A.; Boileau C.;
Hum. Mutat. 30:E682-E691(2009)
Cited for: VARIANTS FHCL1 PRO-254; TYR-356; TYR-358; THR-451 AND SER-826;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.